Scientists test Triple-Threat attack on Tough-to-Treat lymphomas
NCT ID NCT01479842
Summary
This early-stage trial is testing a new combination of three drugs for people whose non-Hodgkin lymphoma has come back after previous treatment. The main goal is to find the safest and most effective dose of a new pill (PCI-32765) when given with two existing drugs (rituximab and bendamustine). Researchers will closely monitor 48 participants for side effects and to see if the three-drug combo is better at controlling the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WALDENSTROM MACROGLOBULINEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Ohio State University Medical Center
Columbus, Ohio, 43210, United States
Conditions
Explore the condition pages connected to this study.